



18 March 2024  
EMA/49114/2024  
Human Medicines Division

## Overview of (invented) names reviewed in February 2024 by the Name Review Group (NRG)

Adopted at the CHMP meeting of 18-21 March 2024

	NRG meeting 13-14 Feb 2024		NRG meeting 16-17 April 2024		NRG meeting 18-19 June 2024		NRG meeting 24-25 September 2024		NRG meeting 19-20 November 2024		2024 total	
	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected
Proposed (invented) names*	69	35									<b>69</b>	<b>35</b>
Justification for retention of (invented) name **	8	4									<b>8</b>	<b>4</b>

\*Includes invented names, INN+MAH/TM and re-use applications.

\*\*In case of objections to the proposed (invented) name(s), the applicant may justify the retention of the proposed invented name using the relevant justification form available on the EMA website.

**Official address** Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands  
**Address for visits and deliveries** Refer to [www.ema.europa.eu/how-to-find-us](http://www.ema.europa.eu/how-to-find-us)  
**Send us a question** Go to [www.ema.europa.eu/contact](http://www.ema.europa.eu/contact) **Telephone** +31 (0)88 781 6000

An agency of the European Union



	NRG meeting 13-14 Feb 2024		NRG meeting 16-17 April 2024		NRG meeting 18-19 June 2024		NRG meeting 24-25 September 2024		NRG meeting 19-20 November 2024		2024 total	
	Endorsed	Not endorsed	Endorsed	Not endorsed	Endorsed	Not endorsed	Endorsed	Not endorsed	Endorsed	Not endorsed	Endorsed	Not endorsed
Total number of objections raised	71	154									<b>71</b>	<b>154</b>
Similarity with other (invented) name	57	120									<b>57</b>	<b>120</b>
Conveys misleading therapeutic connotations	1	5									<b>1</b>	<b>5</b>
Conveys misleading pharmaceutical connotations	1	1									<b>1</b>	<b>1</b>
Misleading with respect to composition	0	0									<b>0</b>	<b>0</b>
Similarity with INN	7	8									<b>7</b>	<b>8</b>
Inclusion of INN stem	0	0									<b>0</b>	<b>0</b>
Unacceptable qualifiers	0	0									<b>0</b>	<b>0</b>
Conveys a promotional message	0	6									<b>0</b>	<b>6</b>
Appears offensive or has an inappropriate connotation	0	2									<b>0</b>	<b>2</b>
Similarity between name of individual active substance and fixed combinations and/or between fixed combinations	0	0									<b>0</b>	<b>0</b>
Similarity between name of prodrug and related active substance	0	0									<b>0</b>	<b>0</b>
Inclusion of common umbrella segment	0	0									<b>0</b>	<b>0</b>
Potential difficulties in pronunciation	0	5									<b>0</b>	<b>5</b>
Others	5	7									<b>5</b>	<b>7</b>

See *Guideline on the [Acceptability of Names for Human Medicinal Products Processed through the Centralised Procedure \(EMA/CHMP/287710/2014\)](#)* for detailed explanations of criteria used.